Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCA33890 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
INCA33890 + bevacizumab is a combination of two monoclonal antibodies for the treatment of solid tumors. **INCA33890** is a bi-specific monoclonal antibody targeting TGF-beta receptor 2 and PD-1, developed based on Biclonics bispecific antibody technology. It is currently in Phase 1 clinical trials for advanced or metastatic solid tumors including a wide range of cancers[1][3][5][7]. **Bevacizumab** is a recombinant humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A), approved for various solid tumors like colorectal cancer, lung cancer, ovarian cancer, renal cell carcinoma, and others[2][4][6]. Both drugs are administered intravenously. The combination aims to block immunosuppressive and angiogenic pathways to improve antitumor efficacy.
- Other names
- INCA-33890INCA33890INCA 33890bevacizumab
02
Targets
TGFBR2 (TGF-β receptor type 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on INCA33890 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCA33890 + bevacizumab.